To The Moon

Eli Lilly's Donanemab Receives Positive CHMP Opinion for Early Alzheimer's Treatment, Awaits European Commission's Final Decision. Eli Lilly and Company has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion recommending donanemab for the treatment of early symptomatic Alzheimer's disease. This recommendation is aimed at adults with confirmed amyloid pathology who are apolipoprotein E ε4 heterozygotes or non-carriers. The European Commission is expected to make a final regulatory decision on donanemab in the coming months. This development is based on encouraging clinical trial data demonstrating donanemab's potential to slow cognitive and functional decline, marking a significant milestone in Alzheimer's treatment efforts across Europe.Disclaimer: This news brief was created by Public Technologies using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-g

Thanksgiving Day(November 23rd) is around the corner.All financial markets in the United States, including stocks, will be closed for one day.On November 24th,the Nasdaq and New York Stock Exchange en

A modest amount of money can go a long way when it's invested in inexpensive, game-changing businesses.